Macrolide Pharmaceuticals
2015
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Series A
LATEST DEAL TYPE
$20M
LATEST DEAL AMOUNT
7
INVESTORS
Description
Developer of novel antibiotic compounds created to improve the lives of patients suffering from serious infections. The company's fifth-generation macrolide antibiotics harnesses the power of synthetic chemistry and microbiology used in the treatment of serious, multi-drug resistant gram-negative infections, enabling patients to recover quickly from multiple infection conditions.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
- 480 Arsenal Way
- Suite 130
- Watertown, MA 02472
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Macrolide Pharmaceuticals’s full profile, request a free trial.
Macrolide Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series A) | 02-Apr-2018 | $20M | 000.00 | 000.00 | Completed | Pre-Clinical Trials |
| 3. Grant | 26-Mar-2018 | 00.00 | 000.00 | Completed | Pre-Clinical Trials | |
| 2. Early Stage VC (Series A) | 25-Feb-2015 | $22.3M | $22.3M | 000.00 | Completed | Generating Revenue |
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Macrolide Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00.00 | 00 | 00 | 00 | 00 | 00.000 |
Macrolide Pharmaceuticals Competitors (10)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Tetraphase Pharmaceuticals | Formerly VC-backed | Watertown, MA | 000 | 00000 | 00000000000 | 00000 |
| 00000 000000000000 | Venture Capital-Backed | San Diego, CA | 000.00 | 0000000000 | 000.00 | |
| 00000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 0000000000. | |
| 00000 000000000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000000 | 00000 |
| 00000000 | Formerly VC-backed | Allschwil, Switzerland | 000 | 00000 | 000000000 | 00000 |
Macrolide Pharmaceuticals Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| CARB-X | Government | 000 0000 | 000000 0 | |||
| Advent Life Sciences | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Gurnet Point Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| Novartis Venture Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Roche Venture Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
Macrolide Pharmaceuticals Executive Team (11)
6 Former Executives
You’re viewing 5 of 11 executives. Get the full list »Macrolide Pharmaceuticals Board Members (14)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Andrew Myers Ph.D | Macrolide Pharmaceuticals | Co-Founder, Board of Scientific Advisor & Board Member | 000 0000 | |
| Anja Harmeier Ph.D | Roche Venture Fund | Board Member | 000 0000 | |
| Christopher Viehbacher | Gurnet Point Capital | Board Member | 000 0000 | |
| Henry Skinner Ph.D | Novartis Venture Fund | Chairman | 000 0000 | |
| Joseph Zakrzewski | Macrolide Pharmaceuticals | Chairman | 000 0000 |
3 Former Board Members
You’re viewing 5 of 14 board members. Get the full list »